KPTINasdaq United States
Market cap
$48.045 M
$2.12 +8.72%
Close of 7 Aug 2026
Revenue
$146.1M
#2408 by revenue
Earnings
-$196.0M
Loss-making
Shares outstanding
22,662,943
Latest filing cover page
P/E ratio
—
Cap ÷ net income
Where these numbers come from
Share counts and financials for Karyopharm Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.